



TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26599000 Fax: + 91 79 26582100

CIN: L24230GJ1972PLC002126; Website: www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)

Statement of Consolidated Financial Results for the Quarter and Half Year ended 30-Sep-2021

Particulars	Quarter ended (Unaudited)			Half Year ended (Unaudited)		Year ended (Audited)
	30-Sep-2021	30-Jun-2021	30-Sep-2020	30-Sep-2021	30-Sep-2020	31-Mar-2021
Revenue						
Net sales	2103	2120	1985	4223	3999	7886
Other operating income	34	14	32	48	74	119
Revenue from operations (net)	2137	2134	2017	4271	4073	8005
Other income	51	40	6	91	10	57
Total revenue	2188	2174	2023	4362	4083	8062
Expenses						
Cost of materials consumed	369	408	364	777	709	1421
Purchases of stock-in-trade	196	206	273	402	556	1005
Changes in inventories of finished goods, work-in-progress and stock-in-trade	30	(26)	(83)	4	(176)	(279)
Employee benefits expense	389	385	363	774	736	1440
Finance costs	71	68	92	139	194	358
Depreciation amortisation and impairment expense	168	165	165	333	326	658
Other expenses	493	484	465	977	952	1933
Total expenses	1716	1690	1639	3406	3297	6536
Profit before tax	472	484	384	956	786	1526
Tax expense						
Current tax	96	88	72	184	154	334
Deferred tax (Refer Note 6)	44	66	2	110	1	(53)
Short provision of earlier periods	16	-	-	16	-	(7)
Total tax expense	156	154	74	310	155	274
Net profit for the period	316	330	310	646	631	1252
Attributable to :						
- Owners of the company	316	330	310	646	631	1252
- Non controlling Interest	-	-	-	-	-	-
Other comprehensive income						
Items that will not be reclassified subsequently to profit or loss	(4)	(4)	4	(8)	(2)	3
Income tax relating to items that will not be reclassified subsequently to profit or loss	1	2	(1)	3	1	(3)
Items that will be reclassified subsequently to profit or loss	38	(45)	89	(7)	121	156
Income tax relating to items that will be reclassified subsequently to profit or loss	(10)	11	(30)	1	(43)	(56)
Total other comprehensive income	25	(36)	62	(11)	77	100
Total comprehensive Income	341	294	372	635	708	1352
Attributable to :						
- Owners of the company	341	294	372	635	708	1352
- Non controlling Interest	-	-	-	-	-	-
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	84.62	84.62
Other equity excluding revaluation reserves	6134	6046	5446	6134	5446	5753
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):						
Basic	18.63	19.53	18.32	38.16	37.30	73.98
Diluted	18.63	19.53	18.32	38.16	37.30	73.98
Additional Disclosure as per regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015						
Paid up debt capital	1534	1534	2019	1534	2019	1559
Networth	6219	6131	5531	6219	5531	5838
Debenture redemption reserve	216	216	352	216	352	216
Debt equity ratio (in times)	0.60	0.64	0.91	0.60	0.91	0.71
Debt service coverage ratio (in times)	2.35	2.24	1.94	2.29	1.75	1.23
Interest service coverage ratio (in times)	8.52	9.26	6.23	8.89	5.96	6.20
Current ratio (in times)	1.17	1.21	1.17	1.17	1.17	1.13
Long term debt to working capital (in times)	1.75	1.89	2.28	1.75	2.28	2.28
Bad debts to Account receivables ratio (in times)	0.01	0.01	0.01	0.01	0.01	0.01
Current liability ratio (in times)	0.61	0.59	0.55	0.61	0.55	0.59
Total debts to total assets (in times)	0.32	0.32	0.37	0.32	0.37	0.34
Debtors turnover (in times) (Annualised)	5.28	5.39	5.09	5.48	4.99	4.97
Inventory turnover (in times) (Annualised)	3.21	3.19	3.28	3.19	3.41	3.27
Operating margin (in %)	33.3%	33.6%	31.8%	33.4%	32.0%	31.7%
Net profit margin (in %)	14.8%	15.5%	15.4%	15.1%	15.5%	15.6%

Ratios have been computed as follows :-

- (a) Debt equity ratio : Debt / Net worth
Debt: Long term borrowings (incl. current maturities of long term borrowings)
Net worth: Equity share capital + Other equity
- (b) Debt service coverage ratio : (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease) / (Interest on debt and lease + Principal repayments of long term debt including lease payment)
- (c) Interest service coverage ratio: (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease) / Interest on debt and lease
- (d) Current Ratio : Current assets / Current liabilities
- (e) Long term debt to working capital : Long term debt (incl. current maturities of borrowings) / Net working capital
Net Working capital : current assets - current liabilities (excl. current maturities of long term borrowings)
- (f) Bad debts to Account receivables ratio : Allowances for credit loss / Gross trade receivables
- (g) Current liability ratio : Current liabilities / Total liabilities (excl. total equity)
- (h) Total debts to total assets : Total borrowing / Total assets
Total borrowing : long term borrowings + current maturities of long term borrowings + short term borrowings
- (i) Debtors turnover : Net sales / Average trade receivables
- (j) Inventory turnover : Net sales / Average Inventories
- (k) Operating margin % : Revenue from operations (net) - (cost of goods sold + employee benefits + other expenses) + (other income - interest income - Dividend income) / Revenue from operations (net)
- (l) Net profit margin % : Profit after tax / Revenue from operations (net)

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 26-Oct-2021. The auditor have carried out review of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The consolidated financial results include the financial results of sixteen wholly owned subsidiaries.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 **Consolidated Balance Sheet**

Particulars	(Rs. in crores)	
	Unaudited	Audited
	As at 30-Sep-2021	As at 31-Mar-2021
ASSETS		
Non-current assets		
Property, plant and equipment	2970	2758
Capital work-in-progress	532	744
Right-of-use assets	124	126
Goodwill	342	341
Other intangible assets	3650	3840
Intangible assets under development	145	145
Financial assets		
Investments	42	42
Loans	2	2
Other financial assets	59	52
	103	96
Income tax assets (net)	33	56
Deferred tax assets (net)	402	421
Other non-current assets	23	24
Sub-total - Non-current assets	8324	8551
Current assets		
Inventories	2612	2681
Financial assets		
Investments	304	139
Trade receivables	1561	1523
Cash and cash equivalents	315	573
Bank balances other than cash and cash equivalents	30	31
Loans	3	3
Other financial assets	175	121
	2388	2390
Other current assets	357	451
Sub-total - Current assets	5357	5522
Non-current assets held for sale	2	2
	5359	5524
TOTAL - ASSETS	13683	14075

(Rs. in crores)

Particulars	Unaudited	Audited
	As at 30-Sep-2021	As at 31-Mar-2021
EQUITY AND LIABILITIES		
Equity		
Equity share capital	85	85
Other Equity	6134	5753
Sub-total - Equity	6219	5838
Non-current liabilities		
Financial liabilities		
Borrowings	2394	2941
Lease Liabilities	29	22
Other financial liabilities	10	8
	2433	2971
Provisions	377	370
Deferred tax liabilities (net)	83	-
Other non-current liabilities	4	5
Sub-total - Non-current liabilities	2897	3346
Current liabilities		
Financial liabilities		
Borrowings	1944	1884
Lease Liabilities	20	26
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	15	20
Total outstanding dues of creditors other than micro enterprises and small enterprises	1769	2047
Other financial liabilities	293	301
	4041	4278
Provisions	391	431
Current tax liabilities (net)	47	54
Other current liabilities	88	128
Sub-total - Current liabilities	4567	4891
TOTAL - EQUITY AND LIABILITIES	13683	14075

5

Consolidated Statement of Cash Flows

(Rs. in crores)

Particulars	Unaudited	
	Half Year ended 30-Sep-2021	Half Year ended 30-Sep-2020
CASH FLOWS FROM OPERATING ACTIVITIES		
PROFIT BEFORE TAX	956	786
Adjustments for :		
Depreciation, amortization and impairment expense	333	326
Allowance for credit loss (net) *	1	0
Unrealised foreign exchange (gain) / loss, (net)	(64)	51
Loss on sale/discard/write-off of property, plant & equipments *	0	0
Net gain on sale of current investments	(5)	(6)
Finance costs	139	194
Interest income	(1)	(2)
	1359	1349
Adjustments for changes in working capital :		
Trade receivables, loans and other assets	44	8
Inventories	70	(393)
Trade payables, liabilities and provisions	(385)	217
CASH GENERATED FROM OPERATIONS	1088	1181
Direct taxes paid (net of refund)	(184)	(49)
NET CASH FROM OPERATING ACTIVITIES	904	1132


(Rs. in crores)

Particulars	Unaudited	
	Half Year ended 30-Sep-2021	Half Year ended 30-Sep-2020
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipments and intangible assets (including capital work-in-progress and capital advances paid)	(127)	(181)
Proceeds from sale of property, plant & equipments and intangible assets	1	2
Investments in mutual funds (net)	(160)	(554)
Investment in fixed deposits (net)*	(0)	-
Interest received	1	2
NET CASH (USED IN) INVESTING ACTIVITIES	(285)	(731)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from long-term borrowings	-	795
Repayment of long-term borrowings	(383)	(448)
Repayment of short term borrowings (net)	(110)	(789)
Repayment of lease obligations	(14)	(16)
Dividend paid	(254)	-
Finance costs paid	(118)	(144)
NET CASH (USED IN) FINANCING ACTIVITIES	(879)	(602)
NET (DECREASE IN) CASH AND CASH EQUIVALENTS	(260)	(201)
Effect of exchange rate changes on foreign currency cash and cash equivalents	2	6
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	573	662
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	315	467

* Less than Rs. 1 crore

- 6 Deferred tax expense for the period ended 30-Sep-2021 includes Rs. 118 crores relates to MAT credit utilisation.
- 7 The Group has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid-19 may be different from what is estimated as at such date of approval of the financial results and the Group will continue to monitor any material changes to future economic conditions.
- 8 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat
Date : 26-Oct-2021